Why the study?
Does GDF-15 assessment prognosticate all-cause mortality in patients with heart failure?
Does GDF-15 assessment prognosticate all-cause mortality in patients with heart failure?
Answers are grounded in this paper and cite their sources.
GDF-15 is a strong prognostic biomarker for all-cause mortality in heart failure patients and may be useful in a multi-biomarker strategy.
BACKGROUND: Several diagnostic and prognostic biomarkers are being explored in heart failure. GDF-15 belongs to the transforming growth factor β (TGF-β) cytokine family that is highly up regulated in inflammatory conditions. We undertook this systematic review to summarize the current evidence on the utility of GDF-15 as a biomarker in heart failure. DESIGN AND METHODS: Multiple electronic databases for studies that reported the association between GDF- 15 and heart failure were searched using different electronic databases such as MEDLINE, Science Direct, Springer Link, Scopus, Cochrane Reviews, and Google Scholar using pre-defined inclusion- exclusion criteria. RESULTS: Twenty one original studies were identified that included data from 20,920 study participants. GDF 15 was found to be a strong prognosticator of all-cause mortality in heart failure patients. Several studies found the benefit of using GDF-15 as a component of a multi-biomarker strategy in prognosticating patients with heart failure. CONCLUSION: More studies are warranted to elucidate the molecular pathways involving GDF-15 and to see how knowledge about GDF-15 can be used to make therapeutic decisions in the clinic.
No takes yet. Share an insight, caveat, or question.
George et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: